摘要：
英国剑桥孤独症研究中心的最新研究结果表明，子宫里的睾丸激素水平可能会对人今后的社交技能发展产生深远影响。这一发现也许能够解释为什么男性患孤独症的可能性是女性的4倍。
西蒙·拜伦-科恩带领的研究小组对58名1996年和1997年出生的孩子进行研究，他们在这些孩子的母亲怀孕时检测了她们羊水中的睾丸激素水平。这......
摘要：
疲劳是白血病、淋巴瘤和骨髓瘤等血液系统恶性肿瘤患者在缓解期的常见症状，以往一直认为其与贫血和免疫力低下等生理学状况相关。最近，德国柏林charité大学医学中心的dimeo等发表的一项新的研究显示，癌症相关性疲劳并不与上述生理学原因相关，而与患者抑郁和体能受损相关。该研究发表在2004年7月19日在线出版的anno......
血管生成调节因子与肿瘤上一页 ...抑素与放疗联合应用可有协同治疗作用. 将表达血管抑素 的腺病毒瘤内注射到大鼠c6胶质瘤模型,并联合使用放疗,结果观察到它们之间有明显 的协同作用[61]. [在]化疗有效杀灭肿瘤细胞后,给予内皮抑素可阻止肿瘤 的复发. bertolini等[在]b淋巴细胞淋巴瘤小鼠模型上,分别于第3.5.7天经腹腔给予ctx75mg/kg,使肿瘤明显缩小,然后于第15～19天分别给予内皮抑素或者缓冲液,结果内皮抑素可明显抑制肿瘤 的生长,假比如停药后肿瘤继续生长并于第25～29天再给予同样剂量 的ctx或者内皮抑素,结果发现内皮抑素仍然有效而ctx则
5结语 【关注焦点:
护理道德的行为规范 】
无效,表明肿瘤对内皮抑素不会产生耐药[62]. 通过构建腺病毒载体转导内皮抑素可有效控制jc乳腺癌与lewis肺癌模型肿瘤 的生长速度,同时转染内皮抑素可完全控制lewis肺癌 的肺转移[63]. 【健康导读:
三腔管的应用 】
肿瘤血管研究这 一新领域,仍有很多问题有待解决. 血管形成因子诊断肿瘤 的特异性.灵敏性需进 一步提高,需继续寻找高效低毒 的血管形成抑制因子,需进 一步深入研究血管形成抑制因子合并化疗.放疗 的理论基础与具体方法. 总之,随着肿瘤血管基础研究与应用研究 的逐步深入,其[在]临床上必将有着广阔 的应用前景. 【扩展阅读:
高压氧 】
实体肿瘤生长必须依赖持续与广泛 的血管生成. 肿瘤血管生成受血管生成促进因子与血管生成抑制因子 的共同调控. 以血管为靶治疗肿瘤正日益受到人们 的广泛重视. 针对血管形成调节因子 的基因疗法已[在]进行探索. 基因治疗具有明显 的优越性,比如通过基因转移技术可使肿瘤组织局部[在]相当长 的时间内稳定表达血管生成抑制因子,而不需经常注射外源性药物以维持有效浓度;另外,直接以肿瘤组织内皮细胞为靶细胞 的抗血管形成基因治疗则可以避免长期使用肿瘤血管生成抑制因子可能诱导肿瘤出现 的“耐药现象”;且基因治疗 的靶向性更为明显,因而对正常组织血管形成 的影响较小. 抗肿瘤血管生成基因治疗丰富肿瘤综合治疗 的内容.
参照文献
1folkmenj.tumorangiogenesis:therapeuticimplication.nengljmed,1971,285:1182-1186.
2mendelsohnj,howleypm,israelma,etal.themolecularbasisofcanˉ
cer.philadelphia:w.b.saunders,1995,206-232.
3dameronkm,volpertov,tainskyma,etal.controlofangiogenesisinfibroblastsbyp53regulationofthrombospondin-1.science,1994,265:158
2-1584.
4folkmenj.whatistheevidencethattumorsareangiogenesisdepenˉdent?.jnatlcancerinst,1990,82(4):4-6.
5flokmanj,klagsbrunm.angiogenicfactors.nature,1989,339:58.
6flokmanj,watsonk,ingberd,etal.inductionofangiogenesisduringthetransitionfromhyperplasiatoneoplasia.science,1987,235:442.
7carroncp,meyerdm,peggja,etal.apeptidomimeticantagonistoftheintegrinalpha(v)beta3inhibitsleydigcelltumorgrowthanddevelˉopmentofhypercalcemiaofmalignancy.cancerres,1998,58(9):1930-1935.
8thaloord,singhak,sidhugs,etal.inhibitionofangiogenicdifferentiˉationofhumenumbilicalveinendothelialcellsbycureumin.cellgrowthdiffer,1998,9(4):305-312.
9caoy.therapeuticpotentialsofangiostatininthetreatmentofcancer.haematologica,1999,84(7):643-650.
10rakjw,stcroixbd,kerbelrs.consequencesofangiogenesisfortuˉmorprogression,metastasisandcancertherapy.anticancerdrugs,1995,6:3-18.
11zolotav,gerokostaa,melachrinoum,etal.microvesseldensity,proˉliferatingactivity,p53andbcl-2expressioninsituductalcarcinomaofthebreast.anticancerres,1999,19(4b):3269-3274.
12hanahand,folkmanj.patternsandemergingmechanismsoftheanˉgiogenicseichduringtumorigenesis.cell,1996,86(3):353-364.13.malsonpiewepc,suric,jonespf,etal.angiopoietin-2,anaturalanˉtagonistfortie-2thatdisruptsinvivoangiogenesis.science,1997,277(5322):55-60.
14suric,jonespf,patans,etal.requisiteroleofangiopoietin-1:aligandforthetie-2receptorduringembryonicangiogenesis.cell,1996,87(7):1171-1180.
15valenzueladm,griffithsj,rojasj,etal.angiopoietin3and4:divergˉinggenecounterpartsinmouseandman.procnatlacadsciusa,1999,96(5):1904-1909.
16stratmanna,risauw,platekh,etal.celltype-specificexpressionofangiopoietin-1andangiopoietin-2suggestsaroleinglioblastomaangiogenesis.amjpatho,1998,153(5):1459-1466.
17zagzagd,amirnovinr,grewma.vascularapoptosisandinvolutioningliomasprecedeneovascularization:anovelconceptforgliomagrowthandangiogenesis.labinvest,2千,80(6):837-849.
18bunoneg,vignerip,marianil,etal.expressionofangiogenesisstimˉulatorsandinhibitorsinhumanthyroidtumorsandcorrelationwithclinicalpatho;ogicalfeature.amjpathol,1999,155(6):1967-1976.
19ahmadsa,liuw,jungyd,etal.theeffectsofangiopoietin-1and-2ontumorgrowthandangiogenesisincolincancer.cancerres,2百1,61(4):1255-1259.
20etoht,inoueh,tnankas,etal.angiopoietin-2isrelatedtotumorangiogenesisingastriccarcinoma:possibleinvivoregulationviainducˉtionofproteases.cancerres,2百1,61(5):2145-2153.
21okadabanm,thieryjp,jouanneauj.fibroblastgrowthfacror-2.intjbiochem,2千,32(3):263-267.
22nguyenm.angiogenicfactorsastumormarkers.investnewdrugs,1997,15(1):29-37.
23dietza,rudatv,conradtc,etal.prognosticrelevanceofserumlevelsoftheangiogenicpeptidebfgfinadvancedcarcinomaoftheheadandnecktreatedbyradiochemotherapy.headneck,2千,22(7):666-673.
24obermaira,speiserp,reisenbergerk,etal.influenceofintratumoralbasicfibroblastgrowthfactorconcentrationonsurvivalinovariancanˉcerpatients.cancerlett,1998,130(1-2):69-76.
25salvenp,teerenhovil,joensuuh,etal.ahighpretreatmentserumbasicfibroblastgrowghfactorconcentrationisanindependentpredictorofpoorprognosisinnon-hogkin’slymphoma.blood,1999,94(10):3334-3339.
26liuy,wangjl,changh,etal.breastcancerdiagnosiswithnipplefluidbfgf.lancet,2千,356(9229):567.
27pichonmf,mouling,palludc,etal.serumbfgf(basicfibroblastgrowthfactor)andca153inthemonitoringofbreastcancerpatients.anticancerres,2千,20(2b):1189-1194.
28fujimotok,ichimoriy,kakizoet.increasedserumlevelsofbasicfiˉbroblastgrowthfactorinpatientswithrenalcellcarcinoma.biochembiophysrescommun,1991,180(1):386-392.
29yamanakay,friessh,buchlerm.overexpressionofacidicandbasicfibroblastgrowthfactorsinhumanpancreatiiccancerccrrelateswithadvancedtumorstage.cancerres,1993,53(21):5289-5296.
30nodam,hattorit,kimurat,etal.expressionoffibroblastgrowthfactor2mrnainearlyandadvancedgastriccancer.actaoncol,1997,36(7):695-7百.
31takanamii,tanakaf.tumorangiogenesisinpulmonaryadenocarcinoˉmas;relationshipwithbasicfibroblastgrowthfactor,itsreceptor,andsurvival.neoplasma,1997,44(5):295-298.
32kumarh,heerk,leepw,etal.preoperativeserumvascularenˉdothelialgrowthfactorcanpredictstageincolorectalcancer.c;incanˉcerres,1998,4(5):1279-1285.
33crewjp,o’brient,bicknellr,etal.urinaryvascularendothelialgrowghfactoranditscorrelationwithbladdercancerrecurrencerates.jurol,1999,161(3):799-804.
34salcenp,manpaah,orpanaa,etal.serumvascularendothelialgrowthfactorisoftenelevatedindisseminatedcancer.clincancerres,1997,3(5):647-651.
35salvenp,ruotsalainent,mattsonk,etal.highpre-treatmentserumlevelofvascularendothelialgrowthfactor(vegf)isassociatedwithpooroutcomeinsmall-celllungancer.intjcancer,1998,79(2):144-146.
36hyodoi,doit,endoh,etal.clinicalsignificanceofplasmavascularendothelialgrowthfactoringastrointestinalcancer.eurjcancer,1998,34(13):2041-2045.
37leejk,hongyj,hancj,etal.clinicalusefulnessofserumandplasˉmavascularendothelialgrowthfactorincancerpatients:whichistheoptimalspecimen?intjoncol,2千,17(1):149-152.
38adamsj,carderpj,downeys,etal.vascularendothelialgrowthfacˉtor(vegf)inbreastcancer:comparisonofplasma,serum,andtissuevegfandmicrovesseldensityandeffectsostamoxifen.cancerres,2千,60(1):2898-2905.
39choijh,kimhc,limhy,etal.detectionoftransforminggrowthfacˉtoralphaintheserumofgastriccarcinomapatients.oncology,1999,57(3):236-241.
40shimks,kimkh,hanws,etal.elevatedserumlevelsoftransformˉinggrowthfactor-beta1inpatientswithcolorectalcarcinoma:itsassoˉciationwithtumorprogressionanditssignificantdecreaseaftercurativesurgicalresection.cancer,1999,85(3):554-561.
41beppuk,uchiyamaa,morisakit,etal.elevationofserumhepatoˉcytegrowthfactorconcentrationinpatientswithgastriccancerismediˉatedbyproductionfromtumortissue.anticancerres,2千,20(2b):1263-1267.
42hansu,leejh,kimwh,etal.significantcorrelationbetweenserumlevelofhepatocytegrowthfactorandprogressionofgastriccarcinoma.worldjsurg,1999,23(11):1176-1180.
43talkskl,turleyh,gatterkc,etal.theexpressionanddistributionofthehypoxia-induciblefactorshif-1alphaandhif-2alphainnorˉmalhumantessues,cancers,andtumor-associatedmacrophages.amjpathol,2千,157(2):411-421.
44volmm,koomagir.hypoxia-induciblefactor1(hif-1)anditsrelationshiptoapoptosisandproliferationinlungcancer.anticancerres,2千,20(3a):1527-1533.
45stillk,robsoncn,autzenp,etal.localizationandquantificationofmrnaformatrixmetalloproteinase-2(mmp-2)andtissureinhibitorofmatrixmetalloproteinase-2(timp-2)inhumanbenignandmaligˉnantprostatictissue.prostate,2千,42(1):18-25.
46hanemaaijerr,verheijenjh,maguiretm,etal.increasedgelatinase-aandgelatinase-bactivitiesinmalignantvsbenignbreasttuˉmorsint.jcancer,2千,86(2):204-207.
47michaelm,babicb,khokhar,etal.expressionandprognosticsignifˉicanceofmetalloproteinasesandtheirtissueinhibitorsinpatientswithsmall-celllungcancer.jclinoncol,1999,17(6):1802-1808.
48rueggc,yilmaza,bielerg,etal.evidencefortheinvolvementofenˉdothelialcellintegrinalphavbeta3inthedisruptionofthetumorvasˉculatureinducedbytnfandifn-gamma.natmed,1998,4(4):408-414.
49qinh,moellingerjd,wellsa,etal.transcreptionalsuppressionofmatrixmetalloproeinase-2geneexpressioninhumanastrogliomacellsbytnf-alphaandifn-gamma.jimmunol,1998,161(12):6664-6673.
50hortonmr,mckeecm,baoc,etal.hyaluronanfragmentssynergizewithinterferon-gammatoinducethec-x-cchemokinesmigandinterferon-inducibleprotein-10inmousemacrophages.jbiolchem,1998,273(52):35088-35094.
51preolletc,hanzc,savonac,etal.plateletfactor4modulatesfibrobˉlastgrowthfactor2(fgf-2)activityandinhibitsfgf-2dimerizaˉtion.blood,1998,91(9):3289-3299.
52gentilinig,kirschbaumne,augustineja,etal.inhibitionofhumanumbilicalveinendothelialdellproliferationbythecxcchemokine,plateletfactor4(pf4),isassociatedwithimpaireddownregulationofp21(cipl1/waf1).blood,1999,93(1):25-33.
53griffoenaw,damenca,mayokh,etal.angiogenesisinhibitorsoverˉcometumorinducedendothelialcellanergyint.jcancer,1999,80(2):315-319.
54dabrowskaa,giermasza,marczakm,etal.potentiatedantitumorefˉfectsofinterleukin12andmatrixmetalloproteinaseinhibitorbatimastatagainstb16f10melanomainmice.anticancerres,2千,20(1a):391-394.
55denislj,verweijj.matrixmetalloproteinaseinhibitors:presentachievementsandfutureprospects.investnewdrugs,1997,15(3):175-185.
56macaulayvm,o’byrnekj,saumdersmp,etal.phaseistudyofinˉtrapleuralbatimastat(bb94),amatrixmetalloproteinaseinhibitor,inthetreatmentofmalignantpleuraleffeusions.clincancerres,1999,5(3):513-520.
57primrosejn,bleibergh,danielf,etal.marimastatinrecurrentcolˉorectalcancer:exploratoryevaluationofbiologicalactivitybymeasureˉmentofcarcinoembronicantigen.brjcancer,1999,79(3-4):509-514.
58mendeldb,lairdad,smolichbd,etal.developmentofsu5416,aselectivesmallmoleculeinhibitorofvegfreceptortyrosinekinaseacˉtivity,asananti-angiogenesisagent.anticancerdrugdes,2千,15(1):29
-41.
59fongta,shawverlk,sunl,etal.su5416isapotentandselectiveinhibitorofthevascularendothelialgrowthfactorreceptor(flk-1/kdr)thatinhibitstyrosinekinasecatalysis,tumorvascularezation,andgrowthofmultipletumortypes.cancerres,1999.59(1):99-106.
60lairdad,vaukoczyp.shawverlk,etal.su6668isapotentantianˉgiogenicandantitumoragentthatinducesregressionofestablishedtuˉmors.cancerres,2千,60(15):4152-4160.
61griscellif,lih,cheongc,etal.combinedeffectsofradiotherapyandangiostatingenetherapyingliomatumormodel.procnatlacadsciusa,2千,97(12):6698-6703.
62bertolinif,fusettil,mancusop,etal.endoststin,amantiangiogenicdrug,inducestumorstabilizationafterchemotherapyoranti-cd20therapyinanod/scidmousemodelofhumanhigh-gradenon-hodgkinlymphoma.blood,2千,96(1):282-287.
63sauterbv,martineto,zhangwj,etal.adenovirus-mediatedgenetransferofendostatininvivoresultsinhighleveloftransgeneexoresˉsionandinhibitionoftumorgrowthandmetastases.procnatlacadsciusa,2千,97(9):4802-4807.
摘要：
7月11日，第三军医大学新桥医院神经外科通过切除患者1/6大脑组织，为一位大脑组织硬如鸡蛋壳、智力低下、左腿行动不便的患者成功实施了癫痫病灶切除术，完成了国内首例腊斯默森综合征手术。
今年11岁的患者熊飞(化名)7年前在一场感冒后出现手脚不断抖动、抽搐，眼睛向左斜视，意识短暂丧失，经医院检查诊断为癫痫。通......
